Cell Therapy Catapult will undertake a European market access assessment for the MultiStem product which considers factors such as data requirements for evidence-based decision making, payers' value perceptions and pricing benchmarks.
Keith Thompson, CEO of the Cell Therapy Catapult, said, 'Understanding market dynamics and reimbursement issues is a crucial part of the development of cell therapies such as MultiStem. We are pleased to be using our expertise in this analysis for Athersys, and look forward to helping other UK and international cell therapy organisations move their products towards the market."
'We are happy to be working with the Cell Therapy Catapult, which is widely recognised as a leading European centre for the development of cell therapies, on this and other important projects', commented Gil Van Bokkelen, Chairman and CEO of Athersys. 'The market access assessment will provide information that is important to our further development of MultiStem in Europe and beyond.'
NanoViricides Reports that the Phase I NV-387 Clinical Trial is Completed Successfully and Data Lock is Expected Soon • NNVC • May 2, 2024 10:07 AM
ILUS Files Form 10-K and Provides Shareholder Update • ILUS • May 2, 2024 8:52 AM
Avant Technologies Names New CEO Following Acquisition of Healthcare Technology and Data Integration Firm • AVAI • May 2, 2024 8:00 AM
Bantec Engaged in a Letter of Intent to Acquire a Small New Jersey Based Manufacturing Company • BANT • May 1, 2024 10:00 AM
Cannabix Technologies to Deliver Breath Logix Alcohol Screening Device to Australia • BLO • Apr 30, 2024 8:53 AM
Hydromer, Inc. Reports Preliminary Unaudited Financial Results for First Quarter 2024 • HYDI • Apr 29, 2024 9:10 AM